# A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

> **NCT01064141** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 210 (actual)

## Conditions studied

- Dengue Fever
- Dengue Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
- **BIOLOGICAL:** OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines
- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines
- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)

## Key facts

- **NCT ID:** NCT01064141
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-09
- **Final completion:** 2012-11
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2013-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064141, "A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01064141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*